| Name | Title | Contact Details |
|---|
Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® platform to develop therapies for a variety of ocular conditions, the most advanced of which is ENV515, for the treatment of glaucoma. ENV515 is a novel extended-release formulation of a prostaglandin analogue formulation. It has the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is located in Research Triangle Park, North Carolina.
Nutramax Laboratories, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Nutramax Laboratories, Inc. is based in Edgewood, MD. You can find more information on Nutramax Laboratories, Inc. at www.nutramaxlabs.com
For more than 130 years, Boehringer Ingelheim has been committed to the research, development, and manufacturing of new medications with high therapeutic value for people and animals. As a family-owned pharmaceutical company, Boehringer Ingelheim is able to take a long-term view and invest heavily in research and development. We are proud of addressing some of the most challenging healthcare issues. Our vision – value through innovation – has always characterized our collaborative work, and is for us simultaneously a fundamental requirement and a driving force. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally through 145 affiliates and a total of some 47,500 employees.
Established in 1973, the National Health Foundation (NHF) is an innovative leader in seeking ways to improve the healthcare delivery system. One of the Foundation's first initiatives was the development of a bioengineering program for hospitals. This